サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1520590

ドキソルビシン市場レポート：用途、流通チャネル、地域別、2024年～2032年

Doxorubicin Market Report by Application, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 144 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.03円
ドキソルビシン市場レポート：用途、流通チャネル、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のドキソルビシン市場規模は、2023年に13億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに20億米ドルに達し、2024年から2032年の間に5.33％の成長率（CAGR）を示すと予測しています。

ドキソルビシン（DOX）は、がん治療の化学療法に使用されるジェネリック医薬品です。注射液または凍結乾燥粉末の形態で、末梢挿入型中心静脈カテーテル（PICC）または中心静脈カテーテル（CVC）から静脈内投与するために使用されます。DOXは静脈内投与後、酵素によって速やかに除去され、血漿中で加水分解を受ける。DOXは、乳がん、膀胱がん、カポジ肉腫、リンパ腫、ウィルムス腫瘍、非ホジキンリンパ腫、急性リンパ性白血病など、いくつかの種類のがんの治療に使用されます。

ドキソルビシン市場動向：

がんの有病率の増加が主に世界のドキソルビシン市場を牽引しています。その結果、様々ながん腫を治療するために他の化学療法剤と組み合わせたDOXの使用が増加しています。これに加えて、低侵襲（MI）外科手術に対する需要の高まりや、大規模な手術を受けることができない高齢者の増加が、がん治療療法の一環としてDOXを好む傾向を強めています。各国政府もまた、静脈内遊離療法やオンチップ生化学分析のためのデジタルマイクロフルイディクスなど、臨床腫瘍学の技術的進歩を支援するイニシアチブを実施しています。また、がん治療に対する啓蒙活動も活発化しています。その結果、DOXの需要は大幅に増加しています。さらに、研究者は技術的に高度なDOX製剤を開発するため、臨床試験にかなりの額を費やしています。さらに、先進的なDOX製剤を用いた臨床試験のための提携だけでなく、M&Aの増加も、今後数年間の市場に明るい展望をもたらすと予想されます。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のドキソルビシン市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：用途別

  • 乳がん
    • 市場動向
    • 市場予測
  • 卵巣がん
    • 市場動向
    • 市場予測
  • 多発性骨髄腫
    • 市場動向
    • 市場予測
  • カポジ肉腫
    • 市場動向
    • 市場予測
  • 白血病
    • 市場動向
    • 市場予測
  • 骨肉腫
    • 市場動向
    • 市場予測
  • 子宮内膜がん
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：流通チャネル別

  • 病院および薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Accord Healthcare Ltd.（Intas Pharmaceuticals Limited）
    • Baxter International Inc.
    • Cadila Pharmaceuticals
    • Cipla Inc.
    • Hikma Pharmaceuticals PLC
    • Meiji Holdings Co. Ltd.
    • Novartis AG
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
  • Figure 2: Global: Doxorubicin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2023
  • Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2023
  • Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Global: Doxorubicin Industry: SWOT Analysis
  • Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
  • Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Doxorubicin Market: Competitive Structure
  • Table 6: Global: Doxorubicin Market: Key Players
目次
Product Code: SR112024A5677

The global doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.33% during 2024-2032.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and distribution channel.

Breakup by Application:

Breast Cancer

Ovarian Cancer

Multiple Myeloma

Kaposi Sarcoma

Leukemia

Bone Sarcoma

Endometrial Cancer

Others

Breakup by Distribution Channel:

Hospital and Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:

  • How has the global doxorubicin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global doxorubicin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global doxorubicin market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Doxorubicin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Kaposi Sarcoma
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Leukemia
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Bone Sarcoma
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Endometrial Cancer
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital and Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Online Stores
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Baxter International Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Cadila Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cipla Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Hikma Pharmaceuticals PLC
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Meiji Holdings Co. Ltd.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Novartis AG
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Pfizer Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis